Literature DB >> 10709847

Kinetics of peptide uptake and tissue distribution following a single intranasal dose of peptide.

B Metzler1, S M Anderton, S P Manickasingham, D C Wraith.   

Abstract

We have previously used intranasal (i.n.) peptide application to induce mucosal tolerance in experimental autoimmune encephalomyelitis (EAE). This strategy, however, appeared to give rise to similar phenomena of tolerance observed as a result of systemic administration of soluble antigenic peptide. We were interested, therefore, in the uptake and tissue distribution of peptide following i.n. treatment. In the H-2u mouse model of EAE, the highly tolerogenic peptide analogue Ac1-9[4Y] of myelin basic protein (MBP) displays high affinity binding to Au MHC class II. For the purpose of the present study this peptide was synthesised to contain a tritiated acetyl group and a protocol was developed to recover radioactivity in solubilised tissues taken at various times after [3H]Ac1-9[4Y] i.n.. Radiolabel loads of the lung and gastro-intestinal tract were initially high but declined rapidly. Radiolabel uptake by blood and lymphoid tissues followed similar kinetics with peak levels around 2.5-4 hours after i.n. administration. Concentrations were high in the draining cervical lymph nodes (CLN) but also reached significant levels in the spleen and 'nondraining' inguinal lymph nodes. The presence of intact antigenic peptide was demonstrated in spleens and CLN from Ac1-9[4Y] i.n. treated mice. Cell suspensions prepared from these tissues at selected time points after peptide i.n. were able to stimulate peptide-specific T cell lines up to at least one day after peptide i.n., suggesting long lasting formation of stable Au-Ac1-9[4Y] complexes in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10709847     DOI: 10.3109/08820130009105145

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  9 in total

1.  Single dose intranasal administration of retinal autoantigen generates a rapid accumulation and cell activation in draining lymph node and spleen: implications for tolerance therapy.

Authors:  A D Dick; V Sharma; J Liversidge
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

2.  Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice.

Authors:  C Aspord; C Thivolet
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

3.  Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor: structure optimization and pharmacokinetics.

Authors:  Rahmawati Ridwan; Paul Kiptoo; Naoki Kobayashi; Scott Weir; Michael Hughes; Todd Williams; Rondang Soegianto; Teruna J Siahaan
Journal:  J Pharmacol Exp Ther       Date:  2009-12-21       Impact factor: 4.030

4.  Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection.

Authors:  Georgia Fousteri; Jason R Chan; Yanan Zheng; Chan Whiting; Amy Dave; Damien Bresson; Michael Croft; Matthias von Herrath
Journal:  Diabetes       Date:  2010-09-23       Impact factor: 9.461

5.  Controlling immune response and demyelination using highly potent bifunctional peptide inhibitors in the suppression of experimental autoimmune encephalomyelitis.

Authors:  P Kiptoo; B Büyüktimkin; A H Badawi; J Stewart; R Ridwan; T J Siahaan
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

6.  Isolation and characterization of human interleukin-10-secreting T cells from peripheral blood.

Authors:  Graziella Mazza; Catherine A Sabatos-Peyton; Rachel E Protheroe; Andrew Herman; John D Campbell; David C Wraith
Journal:  Hum Immunol       Date:  2010-01-07       Impact factor: 2.850

7.  The Mechanism of Action of Antigen Processing Independent T Cell Epitopes Designed for Immunotherapy of Autoimmune Diseases.

Authors:  Ella R Shepard; Anja Wegner; Elaine V Hill; Bronwen R Burton; Sarah Aerts; Evelien Schurgers; Brecht Hoedemaekers; Sky T H Ng; Heather B Streeter; Lotta Jansson; David C Wraith
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 7.561

Review 8.  Manipulating antigen presentation for antigen-specific immunotherapy of autoimmune diseases.

Authors:  Heather B Streeter; David C Wraith
Journal:  Curr Opin Immunol       Date:  2021-04-18       Impact factor: 7.486

Review 9.  Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases.

Authors:  Naomi Richardson; Sky T H Ng; David C Wraith
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.